Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit

June 23, 2017 updated by: Tak Kyu Oh, Seoul National University Bundang Hospital

Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit(ICU) for Postoperative Analgesia After Open Colon Resection: a Double Blind Randomized Controlled Trial

The Transversus Abdominis Block (TAP) block is known to be an effective means of reducing patient pain after abdominal surgery. In the meantime, the general TAP block has been studied in patients who were in the recovery room and the ward after surgery. The purpose of this study was to determine the effect of pain reduction and opioid saving effects in patients with TAP block in ICU settings.

Study Overview

Detailed Description

This study is a prospective study in a single institute of Seoul National University Bundang Hospital and is assigned to the test group and the control group by random assignment. In both groups, PCA (Patient Controlled Analgesia) was used as a post-operative pain control modality. In the Intervention group, a 0.25% Bupivacaine was used for transverse nerve block , and normal saline was used for placebo(control) group

The TAP block will be performed within 1 hour after entering the intensive care unit (ICU) in double blinded state

Study Type

Interventional

Enrollment (Anticipated)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Gyeong gi do
      • Seongnam-si, Gyeong gi do, Korea, Republic of, 13620
        • Recruiting
        • Department of Anesthesiology and Pain department
        • Contact:
        • Principal Investigator:
          • In Ae Song, M.D Ph.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults over 20 years of age
  • Patients who entered the intensive care unit for monitoring and recovery after colonic resection through laparotomy
  • Patients who voluntarily sign a written informed consent and know they have the right to withdraw their consent at any time.

Exclusion Criteria:

  • Patients who are unconscious and require sedation below the Richmond Agitation Sedation Scale (-2) Patients who need continuous renal replacement therapy, cardiopulmonary bypass Patients with a history of allergic reactions to local anesthetics Patients resistant to narcotic analgesics (users of existing long-term narcotic analgesics) Patients who can not use self-analgesic treatment Patients who underwent surgery for organs other than abdomen and pelvis Patients with severe blood clotting disorders with a Prothrombin Time International normalized ratio of 2.0 or greater and Platelet less than 50,000

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TAP group
Drug: 0.25% Bupivacaine, 0.5mL/kg
Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
Ultrasound guided TAP block
Sham Comparator: Placebo group
Drug: 0.9% Normal Saline, 0.5mL/kg
Ultrasound guided TAP block
0.9% Normal Saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
opioid consumption up to 24 hours
Time Frame: 24hour after TAP block
The total amount of IV Fentanyl (10mcg/cc) used by the patients for 24 hours. Patient Controlled Analgesia will be used.
24hour after TAP block

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
resting pain score
Time Frame: 2hour, 6hour, 12hour, 24hour after TAP block
resting Numeric Rating Scale, 0-10, 0= no pain, 10= most severe pain
2hour, 6hour, 12hour, 24hour after TAP block
Nausea score
Time Frame: 2hour, 6hour, 12hour, 24hour after TAP block
Nausea score, 0=none, 1=nausea symptom, 2- nausea requiring treatment, 3=vomiting
2hour, 6hour, 12hour, 24hour after TAP block
sedation score
Time Frame: 2hour, 6hour, 12hour, 24hour after TAP block
0- awake, 1- mild sedation, easy to rouse, 1s= asleep, easy to rouse, 2-moderate sedation, unable to remain awake, 3- difficult to rouse
2hour, 6hour, 12hour, 24hour after TAP block

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: In Ae Song, M.D. Ph.D., Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

July 1, 2017

Primary Completion (Anticipated)

December 31, 2017

Study Completion (Anticipated)

December 31, 2017

Study Registration Dates

First Submitted

June 20, 2017

First Submitted That Met QC Criteria

June 23, 2017

First Posted (Actual)

June 26, 2017

Study Record Updates

Last Update Posted (Actual)

June 26, 2017

Last Update Submitted That Met QC Criteria

June 23, 2017

Last Verified

June 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

It can be shared after request to principal investigator (T.K Oh or I.A Song)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colon Neoplasm

Clinical Trials on 0.25% Bupivacaine, 0.5mL/kg

3
Subscribe